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Molecular signatures specific to particular tumor
types are required to design treatments for resistant
tumors. However, it remains unclear whether tumors
and corresponding cell lines used for drug develop-
ment share such signatures. We developed similarity
core analysis (SCA), a universal and unsupervised
computational framework for extracting core molec-
ular features common to tumors and cell lines. We
applied SCA to mRNA/miRNA expression data from
various sources, comparing melanoma cell lines
and metastases. The signature obtained was associ-
ated with phenotypic characteristics in vitro, and the
core genes CAPN3 and TRIM63 were implicated in
melanoma cell migration/invasion. About 90% of
the melanoma signature genes belong to an intrinsic
network of transcription factors governing neural
development (TFAP2A, DLX2, ALX1, MITF, PAX3,
SOX10, LEF1, and GAS7) and miRNAs (211-5p,
221-3p, and 10a-5p). The SCA signature effectively
discriminated between two subpopulations of mela-
noma patients differing in overall survival, and classi-
fied MEKi/BRAFi-resistant and -sensitive melanoma
cell lines.INTRODUCTION
Genome-wide profiling approaches have provided molecular
insight into cancer initiation and progression, promoting the
development of targeted drugs for personalized treatment (Gon-
zalez-Angulo et al., 2010). However, cancer treatments targeting840 Cell Reports 13, 840–853, October 27, 2015 ª2015 The Authorsdrivermutations are prone to resistance development, due to ge-
netic and epigenetic tumor heterogeneity. Tumor cell-type- or
lineage-specific expression characteristics were identified as
key predictors of responses to several compounds in a screen
of 479 cancer cell lines of 36 different tumor types (Barretina
et al., 2012). Cancer-derived cell lines also are used in drug dis-
covery, but may differ from the tumor of origin (Ertel et al., 2006;
Gillet et al., 2013; Masters, 2000). In tumors, different cell types
interact with each other and the tumor microenvironment,
whereas cell lines are essentially clonal. Culture conditions and
long-term passaging select the most adapted (potentially artifi-
cial) patterns of gene expression, resulting in differences in
gene expression and epigenetic status between cell lines and tu-
mors (van Staveren et al., 2009). The unsupervised clustering of
whole-transcriptome expression data clearly separates cell lines
from tumor samples, even if they contain the same mutations
(Domcke et al., 2013). We therefore need to identify significant
similarities in gene expression between cancer-derived cell lines
and tumors that might be masked by differences due to biolog-
ical growth conditions.
Differential gene expression analyses have identified differ-
ences, but not core similarities, between cell lines and tumors
for particular cancers. Comparisons of cell lines and tumors on
this basis are uninformative, as they simply separate in vivo
and in vitro samples (Domcke et al., 2013). Supervised gene lists
can be used to identify suitable tumor models from cancer cell
lines (Dancik et al., 2011; Gillet et al., 2011; Uva et al., 2010), or
similarities between cancer cell lines and their tumors of origin
can be scored with a tissue similarity index (TSI). This method
uses expression data, without identifying the features underlying
the similarity (Sandberg and Ernberg, 2005).
We designed a computational framework for the unsupervised
extraction of core (= signature) molecular features common to
tumors and cell lines. Characterization of this core should pro-
vide information about phenotypic in vitro and clinical in vivo
characteristics, facilitating lineage-specific approaches. This
approach is unique in its use of similarities rather than differ-
ences and its retention of weakly expressed genes. Similarity
core analysis (SCA) uses a pan-cancer comparative approach
to detect tumor cell lineage-specific genes also expressed
in vitro, for a given tumor type, corresponding to subtle, biolog-
ically meaningful changes in a given lineage. It correctly identi-
fied a melanoma-specific molecular signature including genes
for migration and invasion proteins, such as TRIM63 and
CAPN3, and it underlies melanoma survival.
A similar analysis of microRNA (miRNA) highlighted a regula-
tory network connecting lineage-specific miRNAs (miR-211,
221, and 10a), transcription factors (e.g., MITF, TFAP2A,
SOX10, and DLX2), and target genes potentially involved in
phenotype switching. These specific, biologically relevant fea-
tures demonstrate the utility of SCA for identifying lineage-spe-
cific expression cores relevant for tumor biology. SCA is suitable
for use with all tumor cell types. Here we applied it to mRNA and
miRNA data for melanoma tumors and cell lines.
RESULTS
SCA Identifies a Melanoma-Specific Expression
Signature
We applied unsupervised hierarchical clustering to gene expres-
sion profiles from tumors and cell lines (Table S1). Melanoma tu-
mors and derived cell lines clustered separately, as is the case
for other cancer types (Gillet et al., 2011), whether we used
global mRNA levels (17,322 unique genes) (Figure S1A), the
5,000 genes with the most variable expression (Figure S1B), or
244 multidrug resistance (MDR) genes (Figure S1C).
We then developed a computational framework, SCA, to
extract cancer type-specific gene expression patterns by
comparing the proximity of melanoma cell lines to melanomas
and other tumor types. Using expression profiles for 240 tumor
samples from eight cancer types and 63 melanoma cell lines
(Table S1), we generated 1 3 106 subsets of expression levels
for 20 randomly selected genes (randomly selected contexts
[RSCs]).
For each RSC, we used principal component analysis (PCA) to
capture the characteristic gene expression pattern for each tu-
mor type and to reduce dimensionality, generating a different
PCA space for each RSC. We decreased the number of dimen-
sions to the first eight components for each space.We converted
the PCA space into a correlation space by projecting the 240 tu-
mors, correlating the expression profile of each tumor with that
of each of the eight components. We then reduced the data
again by computing the Euclidean centroid for each tumor type
from the coordinates of its 30 tumors. The candidate cell line
then was projected similarly into the correlation space, and we
calculated the Euclidean distances between the cell line and
the centroid for each tumor type (Figure S1D).
We evaluated the representation of melanoma specificity by
selecting spaces for which the cell line position in the eight-
dimensional correlation space was twice as close to the mela-
noma centroid as to any other centroid. The contribution of
genes contribution to melanoma specificity was evaluated by
calculating their frequency of occurrence in the RSCs corre-Csponding to the selected spaces, with respect to all the RSCs
generated. Fisher’s exact test was used to evaluate the signifi-
cance of enrichment. Finally, genes were ordered by decreasing
contribution to melanoma specificity (increasing p value). An SD
median (SDM) score was generated to take inter-cell line vari-
ability into account and to identify the top 100 genes (Figure 1A).
The top 100 genes (Table S1) of the mRNA signature defined
by SCA (Figure S1E; SCA-MEL-mRNA signature or SCA-MEL-
mRNA-100) showed expression to be more similar in the 30 mel-
anomas and 63melanoma cell lines than betweenmelanoma cell
lines and other tumor types. The numbers of contributing sam-
ples and tumor types were not exhaustive, but SCA can manage
larger amounts of data if required.
We used literature vector analysis (LitVAn) to search for terms
overrepresented in our signature from publications relating to the
SCA-melanoma-mRNA signature (Akavia et al., 2010). Signifi-
cant enrichment was observed for five terms as follows: melano-
cyt, melanoma, catenin, pigment, and tyrosinas (Figure 1B).
These terms were linked to 36 of the 100 SCA genes, consistent
with SCA yielding a cancer type-specific expression signature
(Table S1).
The SCA signature was specific to melanoma, separating the
210 tumor samples (30 samples3 7 different cancer types) from
the 30 melanoma samples and 63 melanoma cell lines in
unsupervised analysis (Figure 1C). Of the SCA-melanoma-
mRNA-100 signature, 45 genes were underexpressed (45DN)
in melanomas, the other 55 being overexpressed (55UP) (Fig-
ure 1C; Table S1). Melanoma cell lines andmelanomas clustered
together, in two clear subgroups (Figure 1D), in analyses based
on the SCA-melanoma-mRNA signature. This suggests that
SCA identified a melanoma-specific signature potentially useful
for comparisons of cell lines and tumors. The 55 overexpressed
SCA genes were significantly enriched in terms associated with
melanoma biology, such as melanocyt, melanoma, pigment,
tyrosinas, waardenburg, SOX10, neural, and MITF (Table S1),
whereas no such enrichment was observed for the other 45
genes (Figure 1E). We therefore focused on the 55UP SCA-mel-
anoma-mRNA signature, which seemed to capture melanoma
specificity. The overexpression of these genes in melanoma
samples also identifies them as suitable targets for loss-of-func-
tion approaches.
Thus, SCA can extract a tumor cell lineage-specific signature
from expression data for multiple cancers. Melanoma cell lines
with this signature are relevant models of their in vivo counter-
parts, as illustrated below.
The SCA-Melanoma-mRNA-55UP Signature Is
Correlated with Phenotypic Characteristics In Vitro
We investigated the correlation between SCA-melanoma-
mRNA-55UP signature expression and in vitro behavior. We ob-
tained expression profiles for 23 independent melanoma cell
lines not used in the SCA analysis, in house, with a microarray
platform different from that used to generate the previous tumor
dataset. Two characteristic groups (groups 1 and 2) were ob-
tained for clustering with the SCA-MEL-mRNA-55UP signature
(Figure 2A). Two well-separated groups (groups 1b and 2b)
also were obtained (Figure S2) when clustering with the SCA-
MEL-mRNA-100 signature. In this second analysis, SK29, Mull,ell Reports 13, 840–853, October 27, 2015 ª2015 The Authors 841
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Figure 1. SCA Identifies a Melanoma-Specific Gene Expression Core
(A) SCA flowchart for mRNA. Gene expression data for eight different tumor types (Ma, melanoma; Co, colon; Ov, ovary; Br, breast; Lu, lung; Li, liver; Ew, Ewing
sarcoma; Ne, neuroblastoma) were acquired and preprocessed to generate randomly selected contexts (RSCs) or packs of 20 arbitrarily chosen genes. SCA
extracts cancer type-specific gene expression patterns for in vitro and in vivo comparisons, by measuring the proximity of cancer cell lines (melanoma) to tumors
of the same type (melanoma) and comparing this proximity with that to other tumor types in PCA-based correlation spaces corresponding to one million RSCs.
These spaces were screened with a criterion based on the minimal distance between melanoma cell lines and the melanoma centroid. The genes with the largest
contribution to melanoma specificity were identified by calculating gene enrichment in the selected spaces and identifying a core of 100 genes (SCA signature).
(B) The SCA-melanoma signature is enriched in melanoma-related terms. Literature vector analysis (LitVAn) showed that 36 of the 100 core genes (gray) were
linked to five significantly enriched terms (red) (Table S1). Note that the terms melanocyt and tyrosinas are deliberately truncated to act as wild cards.
(C) Unsupervised clustering of 240 tumor samples from eight different cancer types and 63 melanoma cell lines based on the SCA signature clearly discriminates
between melanoma samples and other samples. The SCA-melanoma-mRNA signature consists of 55 overexpressed (55UP) and 45 underexpressed
genes (45DN).
(D) The melanoma branch of the dendrogram shows the coclustering of melanoma cell lines (black) and melanomas (blue).
(E) Melanoma specificity is determined by 55UP genes. LitVAn was performed on the 45DN and 55UP core genes separately. The 55 UP core displayed
enrichment for eight terms (Table S1).and Gerlach melanoma cell lines shifted from group 1 to group 2,
suggesting that these cell lines were less representative of the
two groups. This is consistent with the previous finding that842 Cell Reports 13, 840–853, October 27, 2015 ª2015 The Authors14% of 536 profiled melanoma cell lines were intermediate be-
tween proliferative and invasive phenotypes (Widmer et al.,
2012).
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Figure 2. In Vitro Phenotypic Characteris-
tics of Melanoma Cell Lines Are Correlated
with SCA-Melanoma-mRNA Signature
(A) Of the independent melanoma cell lines, 23 not
used for SCA were profiled and used as the
validation set. These melanoma cell lines were
clustered using the 55UP gene core. Two major
clusters of cell lines were obtained. Confidence
in clusters is indicated with bootstrap values
(approximate unbiased p value, AU). The major
classes are independent (p = 0.4639) of mutations
of BRAFV600E (B), NRASQ61K,L,R (N), or wild-type
status for BRAF/NRAS (W). Five cell lines of cluster
1 (G1, T1, 501mel, MNT-1, and SKMel3) and five
cell lines of cluster 2 (WM1366, WM793, WM852,
Lu1205, and A375M) were chosen for further
phenotypic analyses.
(B) 55UP expression heatmap shows the ten
chosen melanoma cell lines (2.3 < log2 expression
intensity < 14.8).
(C) Phenotypic characterization of cluster 1 and 2
melanoma cell lines in vitro. Wound scratch anal-
ysis was performed as a surrogate for migratory
capacity, Matrigel invasion assay for invasive ca-
pacity, subcutaneous tumor growth for tumori-
genic potential, and doubling time for proliferation
rate. In general, cluster 2 cell lines had greater
migratory and invasive capacities and were more
tumorigenic, but less proliferative than cluster 1
cell lines (Mann-Whitney test, *p < 0.05).
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We analyzed the association between SCA-MEL-mRNA-
55UP and in vitro behavior, assessing migratory, invasive,
tumorigenic, and proliferative potentials. Four representative
melanoma cell lines were chosen from each subgroup for further
analysis (Figure 2B). The cell lines of group 1 (G1, T1, 501mel,
MNT-1, and SKMel3) generally expressed melanocyte differenti-
ation-associated genes, such as SOX10, MITF, TFAP2A, TYR,
TYRP1, PAX3, RAB38, DCT, SILV, MLANA, and EDNRB, more
strongly than those of group 2 (WM1366, WM793, WM852,
Lu1205, and A375M). Group 2 cell lines were more aggressive,
with a greater wound-closure capacity, a larger capacity to
invade Matrigel, and a higher tumorigenic capacity after subcu-
taneous injection into nudemice. However, they proliferated less
than group 1 cell lines (Figure 2C). There are, thus, two groups of
melanoma cell lines differing in SCA-MEL-mRNA-55UP signa-
ture expression and phenotypic characteristics.
Transcriptional Control of the SCA-MEL-mRNA-55UP
Signature through MITF and New Targets Involved in
Melanoma Cell Migration and Invasion
The 55UPSCA signature was enriched inMITF target genes (Fig-
ure 3A). We investigated the biological roles of CAPN3 and
TRIM63, two SCA-MEL-mRNA-55UP signature genes with un-
known roles in melanoma biology. Consistent with SCA-based
predictions, CAPN3 and TRIM63 were overexpressed in group
1 melanoma cell lines (Figures 3B and 3C). Small interfering
RNA (siRNA)-mediated MITF knockdown in 501mel melanoma
cells decreased CAPN3 and TRIM63 levels, consistent with
direct regulation by MITF via the predicted MITF-binding sites
(Strub et al., 2011; Figure 3D). TRIM63 repression by siRNA in
501mel cells increased Matrigel invasion capacity (Figure 3E),
whereas CAPN3 repression enhanced wound closure (Fig-
ure 3F), consistent with the greater migration capacity of B16
murine melanoma cells after treatment with calpastatin, a pan-
calpain inhibitor (Raimbourg et al., 2013).
The SCA-MEL-mRNA-28SDE Melanoma Signature
We carried out differential gene expression analysis (fold
change > 2, adjusted p < 0.05) with the SCA-MEL-mRNA-
55UP signature in order to identify genes significantly differen-
tially expressed (SDE) between more and less aggressive
melanoma cell lines. We identified 28 SDE genes. Clustering of
the 23 melanoma cell lines with the SCA-MEL-mRNA-28SDE
signature yielded two characteristic groups (groups 1 and 2)
identical to those for SCA-MEL-mRNA-100 (Figure S3A). Of the
28 SDE genes, 26 were generally overexpressed in less aggres-
sive (group 1) melanoma cell lines. Only RAGE and the non-
coding RNA (uncharacterized LOC100130938) were significantly
more strongly expressed in more aggressive (group 2) mela-
noma cell lines. RAGE overexpression in WM115 primary mela-
noma cells confers a metastatic phenotype (Meghnani et al.,
2014).
SCA Identifies a Melanoma-Specific miRNA Expression
Signature
Unsupervised clustering of global (422) miRNA levels (Fig-
ure S4A) or for the 100 most variably expressed miRNAs (Fig-
ure S4B) clearly separated melanoma cell lines and metastases.844 Cell Reports 13, 840–853, October 27, 2015 ª2015 The AuthorsWe applied SCA to the miRNA profiles of 157 tumor samples (21
samples 3 7 cancer types), with 21 melanoma samples and 51
melanoma cell lines (Table S1). We selected the miRNAs making
the largest contribution to melanoma specificity, by calculating
miRNA enrichment and identifying a core of 51 miRNAs, the
SCA-MEL-miR-51 signature (Figure S4C; Table S1). Melanoma
samples and cell lines formed a distinct branch in the dendro-
gram (Figure 4A) and clustered together (Figure 4B) with this
signature. Of the SCA-MEL-miR-51 genes, 22 were underex-
pressed (22DN) and 29were overexpressed (29UP) in melanoma
samples (Figure 4A). LitVAn allows only mRNA gene symbols for
input. We therefore predicted mRNA targets for the 22DN and
29UP miRNA signatures by sequence-based approaches only.
The predicted miRNA targets had to overlap the SCA-MEL-
mRNA signature to qualify for LitVAn analysis (Table S1). The
predicted target mRNAs of SCA-MEL-miR-29UP genes were
enriched in the melanocyt, waardenburg, melanoma, SOX10,
neural, crest, and MITF terms. The predicted mRNA targets of
SCA-MEL-miR-22DN were enriched in all these terms except
MITF and SOX10 (Figure 4C).
The clustering of 21 independent melanoma cell lines with
SCA-MEL-miR-51 yielded two distinct groups (groups 1 and 2)
identical to those for SCA-MEL-mRNA-100 and SCA-MEL-
mRNA-28SDE (Figure 4D; Figure S2). Thus, SCA extracts mean-
ingful melanoma-associated miRNAs, with expression patterns
correlated with the in vitro behavior of melanoma cell lines. We
performed a conventional differential miRNA expression analysis
between group 1 and group 2 cell lines. Only three miRNAs from
SCA-MEL-miR-51 were SDE (adjusted p value < 0.05). The more
aggressive melanoma cell lines (group 2) had higher levels of
miR-221-3p and miR-10a-5p. miR-221 has been identified as a
potential biomarker of melanoma, as high serum miR-221 levels
are correlated with tumor thickness (Kanemaru et al., 2011) and
higher recurrence risk (Friedman et al., 2012). miR-10a expres-
sion has been linked to gene amplification in melanoma (Zhang
et al., 2006). Group 1 cell lines overexpressed miR-211-5p (Fig-
ure 4E), a melanocyte lineage-specific small non-coding RNA in-
tronic to TRPM1, a target gene of MITF. By upregulating TRPM1
transcription, MITF, which is critical for melanocyte differentia-
tion and survival and for melanoma progression, indirectly drives
miR-211 expression (Levy et al., 2010).
The Melanoma-Specific Regulatory Network Is
Associated with Melanoma Survival
The SCA-MEL-mRNA-55UP signature includes eight transcrip-
tion factor genes as follows: ALX1, DLX2, GAS7, LEF1, MITF,
PAX3, SOX10, and TFAP2A. Ingenuity Pathway Analysis, based
on published findings, and available chromatin immunoprecipi-
tation sequencing (ChIP-seq) datasets for these transcription
factors and their surrogates (Table S1) suggested probable
mutual control for these factors (Figure 5A). Moreover, 90% of
the SCA-MEL-mRNA-55UP signature was connected to at least
one of these transcription factors (Figure 5B); the myelin basic
protein gene (MBP) was potentially regulated by five of the eight
transcription factors (MITF, SOX10, LEF1, PAX3, and TFAP2A).
Significant enrichment was observed for TFAP2A, as 40 of the
SCA-MEL-mRNA-55UP genes had TFAP2A ChIP-seq peaks in
their promoters (p < 3.77 3 1014). MITF, PAX3, SOX10, LEF1,
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DCT
GAS7
CAPN3
RXRG
BIRC7
TFAP2A
TSPAN10
TYR
SOX10
SHC4
PMEL
RAB38
PAX3
MLANA
S100B
LEF1
HILS1
GPM6B
DAAM2
EDNRB
FMN1
C6orf218
GYPC
MBP
PLP1
IGSF11
PRAME
PARVB
TRIM63
MITF
m
R
N
A 
ex
pr
e s
si
on
lo
g2
( F
C )
G
1 T1
50
1m
el
M
N
T−
1
W
M
13
66
W
M
79
3
W
M
85
2
Lu
12
05
CAPN3
TRIM63
G
1 T1
50
1m
el
M
N
T-
1
W
M
13
66
W
M
79
3
W
M
85
2
Lu
12
05
-10
-5
0
5
10
CAPN3
TRIM63
Expression INT (log2)
down median up
siCtrl siMITF
0.0
0.5
1.0
1.5
QR
noisserpxe
ANR
m
M
-FTI
M
MITF-M
siCtrl siMITF
0.0
0.5
1.0
1.5
QR
noisserpxe
ANR
m
3NPAC
CAPN3
siCtrl siMITF
0.0
0.5
1.0
1.5
QR
noisserpxe
ANR
m
36
MIRT
TRIM63
0 3 6 9 12 15
0
25
50
75
100
%
o
f o
pe
n
w
ou
nd
***
siControl
siCAPN3
time (h)siCtrl siCAPN3
0.0
0.5
1.0
1.5
CA
PN
3
m
R
N
A 
ex
pr
es
s io
n
RQ
0
5
10
15
n
u
m
be
ro
f i
nv
ad
in
g 
ce
lls
 (1
0^
2 )
***
siCtrl siTRIM63siCtrl siTRIM63
0.0
0.5
1.0
1.5
TR
IM
63
m
R
N
A 
ex
pr
es
sio
n
R
Q
A B
C
D
E F
2.3 8.2 14.8
Figure 3. SCA-Melanoma-mRNA Genes TRIM63 and CAPN3 Are Potential MITF Targets Involved in Melanoma Cell Migration and Invasion
(A) The 55UP SCA signature was enriched in MITF target genes (30 such genes included; p < 2.7E23, hypergeometric distribution test [Hoek et al., 2006]). Gene
symbols are as follows: red, transcription factor; blue, other; and black, gene of further interest.
(B and C) TRIM63 and CAPN3 expression levels are higher in cluster 1 than in cluster 2 cell lines, according to (B) microarray and (C) qRT-PCR analysis
(representative experiment shown, the error bar represents the SDV of technical triplicates).
(D) MITF downregulation by an siRNA approach decreases the levels of TRIM63 and CAPN3 mRNA.
(E) The repression of TRIM63 by an siRNA approach increases the Matrigel invasion capacity of 501mel melanoma cells after 48 hr. Unpaired t test with Welch
correction, ***p < 104.
(F) The repression of CAPN3 in 501mel cells, by an siRNA approach, increases wound closure. Unpaired t test with Welch correction, ***p < 103.and TFAP2A have been implicated in melanocyte/melanoma
biology (Harris et al., 2010; Koludrovic and Davidson, 2013;
Larue and Delmas, 2006; Medic and Ziman, 2009; Melnikova
andBar-Eli, 2008). The roles of ALX1, DLX2, andGAS7 in theme-
lanocyte lineage are unclear, although they have been linked toCneural tube development (Achim et al., 2014; Chao et al., 2005;
Juriloff and Harris, 2000). Thus, the SCA-MEL-mRNA-55UP
signature identified transcriptional programs involving mela-
noma core genes, driven by melanocyte, neural crest, and
neuronal transcription factors.ell Reports 13, 840–853, October 27, 2015 ª2015 The Authors 845
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Figure 4. SCA Identifies a Melanoma-Specific miRNA Expression Core
(A) Unsupervised clustering of 168 tumor samples from eight different cancer types (Ma, melanoma; Co, colon; Ov, ovary; Br, breast; Lu, lung; Li, liver; Ew, Ewing
sarcoma; Gl, glioblastoma) and 51 melanoma cell lines based on the SCA-melanoma-miRNA signature. Samples are color coded according to their origin.
Melanoma samples (blue) cluster together and are well discriminated on the basis of expression of the 51 core miRNAs. The 51 core miRNAs can be separated
into 22miRNAs generally less strongly expressed inmelanoma than in other cancers (22DN) and 29miRNAs generally more strongly expressed inmelanoma than
in other cancer samples (29UP).
(B) The melanoma branch of the dendrogram shows the coclustering of melanoma cell lines (black) andmelanomas (blue). Note the clustering of one ovary tumor
(red) with the melanoma samples. The melanoma cell lines and tumors separate into two major groups, suggesting that the cell lines of group 1 are more
representative of group 1 melanomas than group 2 melanomas, and vice versa.
(C) LitVAn was performed for the sequence-based predicted targets of the 22DN and 29UPmiRNAs separately. The 29UPmiRNAs were predicted to target 39 of
the 100 core mRNAs and these miRNAs were enriched in the terms melanocyt, waardenburg, melanoma, SOX10, neural, crest, and MITF (Table S1). The 22DN
miRNAs were predicted to target 30 of the 100 core mRNAs; these 30 mRNAs were analyzed by LitVAn and were found to be enriched in the terms melanocyt,
melanoma, waardenburg, crest, and neural (Table S1).
(D) Of the independent melanoma cell lines not used for SCA, 21 were analyzed with the 29UP miRNA core. Two major clusters of cell lines were obtained. The
major classes are independent (p = 0.43) of mutations of BRAFV600E (B), NRASQ61K,L,R (N), or wild-type status for BRAF/NRAS (W).
(E) Differential miRNA analysis was performed between group 1 and group 2 melanoma cell lines with the 29UP miRNAs. Three miRNAs (221-3p, 10a-5p, and
211-5p) were found to be differentially expressed; miR-221-3p and miR-10a-5p were more strongly expressed in group 1 than in group 2 melanoma cell lines,
whereas miR-211-5p was less strongly expressed in group 1 than in group 2 melanoma cell lines.We identified three miRNAs differentially expressed between
melanomas and contributing to a network regulating melanoma
phenotype (Figure 5C). Based on the inversely correlated846 Cell Reports 13, 840–853, October 27, 2015 ª2015 The Authorsexpression levels for these three specific miRNAs, and
sequence-based methods (targetscan), we identified 12 poten-
tial mRNA targets (including MITF, SOX10, TFAP2A, EDNRB,
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and MBP). miR-221 overexpression was associated with
enhanced invasive, migratory, and tumorigenic behavior of mel-
anoma cell lines in vitro. Moreover, miR-221-3p levels were
inversely correlated with expression levels for three potential
target genes encoding key transcription factors (MITF, SOX10,
and TFAP2A). These findings are consistent with reports that in-
hibiting miR-221 expression with antagomiRs decreases inva-
sion and migration by melanoma cells (Felicetti et al., 2008).
The expression of miR-211 and miR-221-3p was correlated
with a weakMITF transcriptional signature, typical of highly inva-
sive melanoma cells (Hoek et al., 2008; Figures S5A and S5B).
miR-211 restores adhesion through NUAK1 repression, sug-
gesting that the MITF-miR-211 axis inhibits invasion by blocking
adhesion (Bell et al., 2014). miR-221-3p targets MITF, thereby
favoring invasion over proliferation. Epithelial-to-mesenchymal
transition (EMT) inducers such as FOSL1 (FRA-1) and TGFB1
or TWIST1 (Figure S5C) have been shown to control the expres-
sion of miR-10a-5p andmiR-221-3p, respectively (Li et al., 2013;
Stinson et al., 2011).
Finally, we assessed the clinical relevance of melanoma SCA
signatures by survival analyses of independent external data-
sets. We downloaded RNA sequencing (RNA-seq) data for 292
melanomametastases (the Cancer Genome Atlas [TCGA] portal,
skin cutaneous melanoma cohort) and clustered them with the
SCA-MEL-mRNA-28SDE signature (Figure 5D). Cluster 2
patients (n = 68), generally displaying underexpression of the
28 genes, survived significantly longer overall (p = 0.0191).
Studies of two other published datasets (Bogunovic et al.,
2009; Jo¨nsson et al., 2010) confirmed that patients overexpress-
ing the 28 SDE core genes had significantly lower overall
(p = 0.0362) and distant metastasis-free (p = 0.0205) survival,
respectively (Figures S5D–S5G). By contrast, the melanoma
phenotype-specific expression (MPSE) gene (n = 97) signature,
derived from melanoma cell lines only, was not informative for
survival analysis (Figures S5H and S5I; Widmer et al., 2012).
However, a 46-gene signature, consisting mostly of immune-
related genes and shown to be informative for patient survival
(Mann et al., 2013), also was discriminant for patients’ survival
in the TCGA dataset (Figures S5J and S5K). Thus, overexpres-
sion of the 28 SDE signature, associated with a less aggressive
phenotype in vitro, was associated with aworse patient outcome
in vivo.Figure 5. The Melanoma-Characteristic Gene Network Is Associated w
Interactions between genes/proteins of the melanoma-specific signature (55UP
publicly available ChIP-seq data (Table S1). The ALX1- and DLX2-related ChIP-s
(A) A core of eight transcription factors (TFs) characteristically overexpressed in m
a specific TF regulates or potentially regulates other TFs. Potential regulation is ev
interactions by IPA (see Table S1 and GEO: GSE67638). For instance, MITF (blu
(B) Over 90% of the melanoma signature genes have been reported or predicted
(C) Sequence-based prediction (mirDIP) and correlation of expression approaches
triangles represent miR. Each potentially binds to sequences located in the 30 reg
(D) Melanoma metastases (SKCM cohort, TCGA portal) were clustered on the b
LOC100130938 was not recognized) generally overexpressed in melanoma and S
of the two principal clusters differed significantly in terms of overall survival (p =
(E) Melanoma metastases (TCGA portal) were clustered on the basis of the expres
between aggressive and non-aggressive melanoma cell lines. The patients of
(p = 0.0031, Mantel-Cox test).
(F) Summary of the model linking molecular in vitro and in vivo features for melan
848 Cell Reports 13, 840–853, October 27, 2015 ª2015 The AuthorsWe performed an equivalent survival analysis with the three
SDE miRNAs (211-5p, 10a-5p, and 221-3p). Patients from the
TCGA cohort with high levels of miR-211-5p and low levels of
miR-10a-5p and miR-221-3p had significantly lower overall
survival (p = 0.0031) (Figure 5E). High miR-211-5p and low
miR-10a-5p and miR-221-3p levels were associated with a
less aggressive phenotype in vitro. The previously published
miRNA-survival signature, consisting of another 18 miRNAs
(Segura et al., 2010), yielded no significant results for analysis
of the TCGA melanoma cohort (p = 0.0606) (Figures S5L
and S5M).
In summary, SCA of melanoma samples revealed molecular
features associated with the cellular and clinical features of mel-
anoma samples, suggesting a melanoma model (Figure 5F).
DISCUSSION
Appropriate in vitro, in cellulo, and in vivomodels are required for
preclinical pipelines for cancer treatment. For ethical, economic,
and biological complexity reasons, cancer cell lines are a good
compromise for deciphering molecular and cellular mechanisms
before testing therapies. Relevant systems, reproducing in vivo
scenarios accurately, are thus required for molecular and cellular
studies. Cell lines have long been used for therapeutic drug
screening. Murine B16 melanoma cells have been widely used,
but with little success. It has become clear that this specific
cell line is useful for addressing particular biological questions,
but not for the development of new treatments for humans, prob-
ably due to differences between this in vitro model and in vivo tu-
mors. Large-scale cell-line panels are increasingly used for drug
screening and omics data generation (Kim et al., 2014). Analyses
of the correlation of molecular features with sensitivity to small-
molecule drugs in many cancer cell lines have highlighted the
need to take lineage-specific features into account (Barretina
et al., 2012; Basu et al., 2013; Cheung et al., 2011). Our SCA
approach could be useful for this. Similarly, tumor samples and
cancer cell lines for specific tumors do not cluster in transcrip-
tomics analyses, suggesting clear differences in gene expres-
sion that may render cell lines inappropriate for use in treatment
development.
SCA identified cancer lineage-specific mRNA/miRNA expres-
sion patterns. This computational approach extracts signaturesith Patient Survival
) were inferred from Ingenuity Pathway Analysis (IPA, literature-based) and
eq data were not available at the time of publication.
elanoma and identified by SCA. Directed arrows of a specific color indicate that
aluated according to the integration of ChIP-seq data, expression, and known
e) regulates TFAP2A, SOX10, LEF1, PAX3, and probably also GAS7.
to be targeted by the core TFs. The color code corresponds to the eight TFs.
used to integrate themelanoma-specificmiRNAandmRNA signatures. Yellow
ion of the indicated mRNA, decreasing the levels of the corresponding mRNA.
asis of the expression of the 28 core genes (27 of 28 genes were exploitable,
DE between aggressive and non-aggressive melanoma cell lines. The patients
0.0191, Mantel-Cox test).
sion of the three core miRNAs generally overexpressed in melanoma and SDE
the two principal clusters differed significantly in terms of overall survival
oma based on SCA is shown.
characteristic of both tissue samples and cell lines. The combi-
nation of lineage specificity and the relevance of the signature
to both in vivo and in vitro conditions make it possible to identify
molecular relationships missed by conventional strategies, such
as differential gene expression analysis and batch removal ap-
proaches comparing cell lines with tumors (Figure S6). SCA
was developed in assuming that cancer cell lines of a specific
lineage retain key transcriptional programs reminiscent of the
original tumor and in the unsupervised extraction of these
programs.
Unlike other methods, SCA identified a molecular mRNA and
miRNA signature in melanoma tumors that was common to mel-
anoma cell lines, suggesting that these cell lines were relevant to
the corresponding tumor samples. This method can be applied
to other tumor types. For melanoma samples, this approach
also did the following: (1) identified new mRNA/miRNAs specific
to the melanocyte lineage; (2) showed that most of the associ-
ated proteins were molecularly linked via eight transcription
factors also included in the signature; and (3) showed that,
according to SCA-MEL-mRNA-55UP and SCA-MEL-miR signa-
tures, aggressive cell lines corresponded to non-aggressivemel-
anomas and vice versa.
This mRNA/miRNA signature is, by design, specific to the
melanocyte lineage. Pharmacological approaches are based
on toxicity and specificity. By using the specificity of this
signature to target these mRNA/proteins and/or miRNAs, it
should be possible to alter their molecular and cellular
functions. For instance, CAPN3 (protease) and TRIM63 (E3
ubiquitin ligase) are produced abundantly by aggressive mela-
nomas and regulate in vitro migration and invasion, respec-
tively. The enzymatic activities of these proteins may induce
the release of toxic products from prodrugs. This general strat-
egy already has been proposed, with tyrosinase as the enzyme
and MITF (the master transcription factor of the melanocyte
lineage) as the target (Sa´ez-Ayala et al., 2013). Such cell
lineage-targeted therapy could be coupled with molecularly
targeted therapy and/or immunotherapy, yielding additional
benefits.
The mRNA components of the SCA-MEL-mRNA signature
include mRNAs for key neural crest and melanocyte transcrip-
tion factors and their targets. MITF and TYR scored highest in
the SCA-MEL-mRNA signature analysis, and our melanoma-
specific signature was highly enriched in MITF target genes
(30 of 55), including melanocyte differentiation genes, such as
MLANA, TYRP1, DCT, and SILV, and genes involved in melano-
some biogenesis, such as MFN2 and RAB38 (Daniele et al.,
2014; Loftus et al., 2002). It has been suggested that RAB7
controls melanoma progression through lineage-specific wiring
of the endolysosomal pathway (Alonso-Curbelo et al., 2014).
Lysosomes and melanosomes have common precursors (Ra-
poso and Marks, 2007). The Cancer Cell Line Encyclopedia
(CCLE) cohort was used to explore expression patterns
specific to melanoma cell lines by comparison with cell lines
for other cancer types. This validates our approach, also using
tumor samples and cell lines to identify lineage-specific
dependences.
SCA-MEL-mRNA highlights a regulatory network including
eight transcription factors (MITF, TFAP2A, ALX1, DLX2, PAX3,CSOX10, LEF1, and GAS7). TFAP2A seems to be a key regulator
of this lineage with significant target enrichment (p < 3.77 3
1014). We identified a new potential regulator of TFAP2A
encoded by a gene upstream from the TFAP2A promoter:
open reading frame 218 on chromosome 6 (C6ORF218) or
long intergenic non-protein coding RNA 518 (LINC00518).
Given its location and strong coexpression with TFAP2A,
LINC00518 may act in cis, regulating the expression of its
neighbor (Luo et al., 2013). TFAP2A loss contributes to pro-
gression from the radial growth phase to the vertical growth
phase in melanoma (Mobley et al., 2012). Our melanoma cell
lines with low levels of TFAP2A and MITF expression had a
more aggressive phenotype in vitro. TFAP2A controls neural
crest differentiation and development and is strongly expressed
in neural crest cells migrating from the cranial folds during neu-
ral tube closure. Homozygous TFAP2A-knockout mice have
neural tube defects and craniofacial and body wall abnormal-
ities (Zhang et al., 1996). ALX1 and DLX2 have similar roles in
cranial neural crest development (Merlo et al., 2000; Uz et al.,
2010). The other transcription factors from our signature,
SOX10, PAX3, LEF1 and GAS7, regulate neural crest and
neuronal development (Betancur et al., 2010; Hung et al.,
2013; Sauka-Spengler and Bronner-Fraser, 2008), highlighting
the lineage specificity of melanoma cells. The transcription fac-
tors identified constitute the core of our proposed regulatory
network. About 90% of the remaining melanoma-specific
signature genes (47 of 55) may be regulated by at least one
of these transcription factors.
Variants of the SCA-MEL-mRNA/miR signature in melanoma
cell lines predict behavior in vitro and melanoma patient sur-
vival. We did not expect tumors to form distinct subclasses
associated with tumor aggressiveness. Further in vitro and
in vivo studies are now required to gain insight into this seren-
dipitously discovered relationship. Aggressive tumors had sig-
natures corresponding to non-aggressive cell lines and vice
versa. This apparent discrepancy probably results from high
and modifiable MITF levels. This transcription factor acts as a
rheostat, determining subpopulation identity (Carreira et al.,
2006). Low MITF levels in melanomas result in invasive cells
with stem-like properties, arrested in G1 phase and efficiently
inducing tumors (Cheli et al., 2011). By contrast, high MITF
levels activate differentiation genes driving melanin production,
such as tyrosinase (TYR) and melanosome biogenesis enzyme
genes (Cheli et al., 2010). Cell lines consist of largely homoge-
neous dividing cells. We considered cell lines to be aggressive
if they invaded, migrated, and formed tumors in nude mice,
even if they divided slowly. Conversely, even rapidly dividing
non-aggressive cell lines did not invade, migrate, or form tu-
mors in mice.
We evaluated the prediction by the SCA signature of MEKi and
BRAFi drug sensitivity in melanoma cell lines. Strong SCA-MEL-
mRNA-28SDE signature expression was associated with sensi-
tivity to MEK and BRAF inhibition (Figures S3B–S3E). Also, we
evaluated the SCA-MEL-mRNA-28SDE signature using publicly
available primary melanoma samples (n = 297, GEO: GSE57715)
andmelanoma cell lines (n = 63, GEO: GSE7127) (Figure 6). Inter-
estingly, the SCA-MEL-mRNA-28SDE separated two groups
of primary melanomas mixed with melanoma cell lines. Afterell Reports 13, 840–853, October 27, 2015 ª2015 The Authors 849
MFN2
GYPC
PARVB
MBP
TRIM63
TSPAN10
BIRC7
RENBP
DCT
TYR
MITF
MLANA
GPM6B
RAB38
PAX3
TFAP2A
CAPN3
IGSF11
EDNRB
ROPN1B
Melanoma cell linePrimary melanoma
cluster 1 cluster 2
-0.5 0.5
-0.5
1.0
cluster 1
cluster 2
Pro
Inv
1.0
cluster 1 cluster 2
0
1
2
3
4
br
e
slo
w
de
pt
h
(m
m)
***
A
B C
Primary melanomas Melanoma cell lines
0.5
Figure 6. SCA Identifies Melanoma Cell
Lines Being Representative of Primary Mel-
anomas that Differ in Breslow Thickness.
(A) Primary melanomas (n = 297, GEO: GSE57715)
and melanoma cell lines (n = 63, GEO: GSE7127)
were clustered using the SCA-MEL-mRNA-28SDE
signature (20 of 28 genes were exploitable in this
dataset). The dendrogram shows two distinct
clusters containing each primary melanomas and
melanoma cell lines.
(B) Primary melanomas of cluster 1 are generally
of lower Breslow depth compared to cluster 2
(***p < 0.0001, Mann-Whitney test).
(C) Scoring of cluster 1 and cluster 2 melanoma
cell lines using melanoma phenotype-specific
expression (MPSE) correlation plot. In this plot,
Pearson correlation coefficients against the
proliferative (x axis) and invasive (y axis) stan-
dard signatures are plotted (Widmer et al., 2012).
Perfect correlation of a melanoma cell line’s
expression signature with the standard invasive
signature would result in a correlation coefficient
(r) = 1 (y axis), and perfect correlation with the
standard proliferative signature in r = 1 (x axis).
According to the MPSE correlation plot, mela-
noma cell lines of cluster 1, which cocluster
with primary melanomas of lower Breslow thick-
ness, are most likely to exhibit an invasive
phenotype.classifying the melanoma cell lines as either proliferative or
invasive using Heuristic Online Phenotype Prediction (HOPP,
Widmer et al., 2012), we noticed that strong SCA-MEL-mRNA-
28SDE expression identified proliferative melanoma cell lines
that coclustered with primary melanomas of deeper Breslow
depth (Figure 6). This provides further support for our SCA
approach, because it is informative for both metastatic and pri-
mary melanoma.
Tumors are heterogeneous with some cells proliferating
and others invading. Invading cells that cannot proliferate do
not induce death rapidly, but the converse may not be
true. We analyzed survival in melanoma metastases, prolifera-
tive cells that were previously invasive; however, melanoma
cells readily switch between these states. There is increasing
evidence for this phenotype switching phenomenon (Hoek
and Goding, 2010). We considered the average expression pro-
files of melanomas to be the predominant phenotypic state of850 Cell Reports 13, 840–853, October 27, 2015 ª2015 The Authorsall melanoma cells within the lesion. A
previously defined invasive signature
(Widmer et al., 2012) did not overlap
with our SCA signature because the
invasive program is common to different
cancers and, thus, not specific to mela-
noma (Figure S3F).
SCA may become a standard tool for
extracting lineage-specific molecular
dependencies for any tumor type.
Increasing computational power will
make it possible to analyze larger co-
horts. SCA can highlight cancer regula-
tory networks operating in vitro and is particularly valuable for
drug development.
EXPERIMENTAL PROCEDURES
SCA
Data Transformation and Context Generation
Expression data for eight tumor types (Table S1) were retrieved from GEO. We
aggregated 30 randomly selected samples from each set into a single dataset,
which was then quantile-normalized for interdisease scaling. This multi-tumor
dataset covered 17,322 genes. A similar miRNA analysis was performed with
21 samples per tumor type, covering 422 miRNAs. One million subsets of
20 randomly selected features (mRNA/miRNA) referred to as RSCs were
generated.
PCA Space Computation and Tumor Projection
For each RSC, PCA was performed on the tumor dataset in the same manner
as singular value decomposition (SVD) was used by Sandberg and Ernberg
(2005), but limited here to the RSC features, whereas Sandberg and Ernberg
used a single signature of 303 genes. We limited the dimensions of the
resulting PCA space to its first eight, assuming the different types of cancer to
be the major source of variance in the tumoral dataset. Tumors used for PCA
space construction were then projected into the space by Pearson correlation
of their expression to yield a new eight-dimensional correlation space.
Euclidean centroids were calculated for each tumor type in this correlation
space. Each cell line was then projected similarly into the correlation spaces
corresponding to each RSC.
Context Selection Based on Disease Similarity and Specificity
We evaluated the ability of each RSC to capture the features making a cell line
uniquely similar to the corresponding disease, with a graphical criterion: its
coordinate distance to the melanoma centroid in the correlation space.
RSCs were considered to be melanoma-specific if the cell line coordinate in
the space was at least twice as close to the melanoma centroid as to any other
centroid (Figure S1D). This selection procedure was performed independently
for each melanoma cell line.
Feature Enrichment Evaluation and Core Generation
For each cell line, feature enrichment in the selected RSCs versus their occur-
rence in the one million generated RSCs was evaluated with Fisher’s exact
test. Features were then ordered by increasing p values, after false discovery
rate correction by the Benjamini-Hochberg method. For core generation, we
pooled the feature-ranking results for all independently analyzed cell lines
and assigned a score (SDM score) to each feature, by calculating the SD of
its rank across cell lines divided by its median rank. After ordering features
in descending order of scores, cores were built by taking the 100 best features
for mRNA and all features with a score above 1.0 for miRNA. The SCA code is
provided as an R script (https://github.com/aoumess/SCA).
Variability of Gene Expression
See the Supplemental Experimental Procedures.
Sample Classification
See the Supplemental Experimental Procedures.
Data Retrieval, Preprocessing, andNormalization of Public Datasets
See the Supplemental Experimental Procedures.
Literature Vector Analysis
See the Supplemental Experimental Procedures.
Survival Analysis
See the Supplemental Experimental Procedures.
Molecular and Cellular Biology Methods
See the Supplemental Experimental Procedures.
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